Publications by authors named "Thomas Haws"

Claim this Profile
A
A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
Eric J Olson, Kelly M Mahar, Thomas F Haws, Michael J Fossler, Feng Gao

Clin Pharmacol Drug Dev· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
John J Lepore, Eric Olson, Laura Demopoulos, Thomas Haws, Zixing Fang

JACC Heart Fail· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.
Eric Olson, Laura Demopoulos, Thomas F Haws, Erding Hu, Zixing Fang

Vasc Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types.
Jeffrey C Webster, Reid M Huber, Rebecca L Hanson, Paul M Collier, Thomas F Haws

Endocrinology· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.
Reid M Huber, Kathleen Murphy, Bowman Miao, John R Link, Mark R Cunningham, Thomas F Haws

Gene· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis